BioRestorative Cost Of Revenue from 2010 to 2025
| BRTX Stock | USD 1.97 0.21 11.93% |
Cost Of Revenue | First Reported 2012-03-31 | Previous Quarter 6.5 K | Current Value 18.2 K | Quarterly Volatility 837 K |
Check BioRestorative Therapies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioRestorative Therapies' main balance sheet or income statement drivers, such as Interest Expense of 12.7 K, Selling General Administrative of 7.7 M or Depreciation And Amortization of 178.1 K, as well as many indicators such as Price To Sales Ratio of 54.99, Dividend Yield of 0.0 or PTB Ratio of 0.69. BioRestorative financial statements analysis is a perfect complement when working with BioRestorative Therapies Valuation or Volatility modules.
BioRestorative | Cost Of Revenue |
Latest BioRestorative Therapies' Cost Of Revenue Growth Pattern
Below is the plot of the Cost Of Revenue of BioRestorative Therapies over the last few years. Cost of Revenue is found on BioRestorative Therapies income statement and represents the costs associated with goods and services BioRestorative Therapies provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is BioRestorative Therapies' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioRestorative Therapies' overall financial position and show how it may be relating to other accounts over time.
| Cost Of Revenue | 10 Years Trend |
|
Cost Of Revenue |
| Timeline |
BioRestorative Cost Of Revenue Regression Statistics
| Arithmetic Mean | 116,020 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 95.22 | |
| Mean Deviation | 100,989 | |
| Median | 165,735 | |
| Standard Deviation | 110,469 | |
| Sample Variance | 12.2B | |
| Range | 280.7K | |
| R-Value | 0.56 | |
| Mean Square Error | 8.9B | |
| R-Squared | 0.32 | |
| Significance | 0.02 | |
| Slope | 13,102 | |
| Total Sum of Squares | 183.1B |
BioRestorative Cost Of Revenue History
About BioRestorative Therapies Financial Statements
BioRestorative Therapies investors use historical fundamental indicators, such as BioRestorative Therapies' Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioRestorative Therapies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 190.6 K | 124.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.